Related Articles
A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer
Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients
Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation
Continuous exposure of non‑small cell lung cancer cells with wild‑type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3
Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment